Lymphoma

Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is Hodgkin disease, and the other types are called non-Hodgkin lymphoma.

Programs + Services


Hematologic Malignancies Program

The Hematologic Malignancies Program at Tufts Medical Center in Boston uses the latest diagnostic techniques to pinpoint your cancer type and provide you with the most effective treatment. Learn more about treatment options available for hematologic malignancies including chemotherapy, radiation therapy and more.
More information about programs and services

Doctors + Care Team

Andreas K. Klein, MD

Andreas K. Klein, MD

Accepting New Patients

Title(s): Associate Chief, Division of Hematology Oncology; Director, Hematologic Malignancies Program; Assistant Director, Bone Marrow and Hematopoietic Cell Transplant Program; Chair, Tufts Health Sciences Campus Institutional Review Boards; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Lymphoma, myeloma, bone marrow transplantation (BMT), immune reconstitution after BMT

View Full Profile for Andreas K. Klein, MD

Cindy Varga, MD

Cindy Varga, MD

Accepting New Patients

Title(s): Medical Oncologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Malignant hematology (plasma cell dyscrasia, leukemia, lymphoma)

View Full Profile for Cindy Varga, MD

Kellie A. Sprague, MD

Kellie A. Sprague, MD

Accepting New Patients

Title(s): Director, Bone Marrow and Stem Cell Transplant Program; Director, Adult Leukemia Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Bone marrow transplantation, acute and chronic leukemia, myelodysplastic syndromes, lymphoma, myeloma, myeloproliferative disorders

View Full Profile for Kellie A. Sprague, MD

Kenneth B. Miller, MD

Kenneth B. Miller, MD

Accepting New Patients

Title(s): Associate Chief, Division of Hematology/Oncology; Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-2600
Fax #: 617-636-8538

Acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), lymphoma, bone marrow and stem cell transplantation

View Full Profile for Kenneth B. Miller, MD

Monika Pilichowska, MD, PhD

Monika Pilichowska, MD, PhD

Title(s): Director, Clinical Hematology and Hematopathology; Director, Hematopathology Fellowship Program; Associate Professor, Tufts University School of Medicine
Department(s): Pathology and Laboratory Medicine
Appt. Phone: 617-636-7216
Fax #: 617-636-7128

Hematology and hematopathology, flow cytometry, surgical pathology and cytology, renal pathology (medical renal disease)

View Full Profile for Monika Pilichowska, MD, PhD

Raymond L. Comenzo, MD

Raymond L. Comenzo, MD

Accepting New Patients

Title(s): Director, Transfusion Services; Director, John C. Davis Myeloma and Amyloid Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Pathology and Laboratory Medicine, Hematology/Oncology
Appt. Phone: 617-636-6454
Fax #: 617-636-3175

Myeloma, amyloidosis, stem cell transplant, transfusion medicine

View Full Profile for Raymond L. Comenzo, MD

Research + Clinical Trials


Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

This is an open-label, dose-escalation Phase 1/2 Study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regiment, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available. 
More information about research and clinical trials